AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock Movers
Bloomberg 2026-06-22 15:08:42
Context: Shares of Apogee Therapeutics and Regenxbio experienced significant movements following major announcements, with Apogee's stock soaring on news of a potential $11 billion acquisition deal with AbbVie, and Regenxbio's shares moving after the company aligned with the FDA on the next steps for its gene therapy drug, Navsunli. The developments have impacted the stock market, with Apogee's shares rising and Regenxbio's shares also reacting to the news. Meanwhile, SpaceX's stock continued its decline following a record IPO.
Key Facts
- Apogee Therapeutics' shares are surging due to news that AbbVie is nearing a deal to acquire the company for nearly $11 billion, as reported by the Financial Times.
- Regenxbio has aligned with the FDA on the next steps for a potential accelerated approval of Navsunli, a gene therapy for Mucopolysaccharidosis II, with the FDA confirming that additional studies of the drug are not required.
- The FDA's confirmation that Regenxbio does not need to conduct additional studies of Navsunli has led to movement in Regenxbio's shares.
- The potential acquisition of Apogee Therapeutics by AbbVie is valued at nearly $11 billion and is expected to be a significant deal in the pharmaceutical industry.
- SpaceX's stock is lower, continuing its slide after a record IPO, according to Bloomberg.